AMSbiopharma, a CRO (Contract Research Organization) belonging to AMSlab Group and specialized in advanced analytical services for the chemical, pharmaceutical, and biopharmaceutical industries, announces the launch of its new Innovation Plan.
The objective is to position the company as a European leader in the global market. This project, funded by the Galician Innovation Agency, marks a crucial step for the company in its mission to support industry players in the drug development process.
With over five years of experience, AMSbiopharma has consistently demonstrated a commitment to innovation. This Innovation Plan aims not only to strengthen the company’s operational capabilities but also to differentiate itself from competitors through the implementation of new analysis and quality control services during drug manufacturing.
Introducing advanced services will be key to ensuring higher-quality and safer products.
Innovation at the core of AMSbiopharma
AMSbiopharma’s Innovation Plan goes beyond improving internal processes, adopting a comprehensive approach that encompasses innovation in services, technology, and organization. At the heart of this approach lies innovative intrapreneurship and the promotion of intangible innovation, a disruptive diversification process that encourages employees to take on an entrepreneurial role within the company, leveraging existing know-how, synergies, and new knowledge. This approach enables AMSbiopharma to develop creative solutions and carry out innovative projects that respond to the ever-evolving market demands.
Additionally, the plan includes the implementation of new technologies such as data encryption and control to enhance traceability and transparency in manufacturing processes, representing a significant technological innovation for the company. This advancement optimizes process efficiency and strengthens the security and reliability of the services AMSbiopharma offers its clients.
Funded by the Galician Innovation Agency
This project is funded by the Galician Innovation Agency as part of the InnovaPeme business aid program under the 2024 call. The project will be carried out over 18 months. To ensure its success, AMSbiopharma has strengthened its team by hiring new staff, selected under strict recruitment criteria.
A boost for biotechnological innovation in Lugo
With this Innovation Plan, AMSbiopharma not only strengthens its competitive position in the market but also contributes to the development of biotechnology in Lugo. The company’s commitment to technological innovation and continuous process improvement will enable it to offer the highest quality services, reaffirming its commitment to excellence in the biopharmaceutical industry.